Mineralys Therapeutics logo

Mineralys Therapeutics

Radnor, PA

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.

mineralystx.com

Company Details

Founded

2020

Employees

Between 10 - 50 employees

Raised

$158,000,000

Headquarters Location

Radnor, PA

Public

Yes

Acquired

No

CEO

Jon CongletonJon Congleton

Founders

BT Slingsby
BT Slingsby

Company Collections

These are collections Mineralys Therapeutics is a part of. Click on the collection name to view similar companies.

Mineralys Therapeutics' Industries

Mineralys Therapeutics' Tech Stack